FibroBiologics Inc. Commo... (FBLG)
0.87
-0.01 (-0.57%)
At close: Apr 04, 2025, 3:38 PM
-0.57% (1D)
| Bid | 0.87 |
| Market Cap | 32.94M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -0.34 |
| PE Ratio (ttm) | -2.57 |
| Forward PE | -6.12 |
| Analyst | Buy |
| Ask | 0.88 |
| Volume | 108,585 |
| Avg. Volume (20D) | 293,259 |
| Open | 0.88 |
| Previous Close | 0.88 |
| Day's Range | 0.85 - 0.93 |
| 52-Week Range | 0.85 - 13.59 |
| Beta | 0.18 |
About FBLG
FibroBiologics, Inc., a clinical-stage cell therapy company, develops and commercializes fibroblast-based therapies in the United States. It is developing CybroCell, for the treatment of degenerative disc disease; CYMS101 to treat multiple sclerosis; and CYWC628 for wound healing. The company is also on the early-stage research of CYTER915, which is designed to regenerate or reinvigorate production of the thymus and/or spleen; CYPS317, for the tr...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 1, 2024
Employees 13
Stock Exchange NASDAQ
Ticker Symbol FBLG
Website https://www.fibrobiologics.com
Analyst Forecast
According to 5 analyst ratings, the average rating for FBLG stock is "Buy." The 12-month stock price forecast is $12, which is an increase of 1274.73% from the latest price.
Stock Forecasts3 months ago
-0.87%
FibroBiologics shares are trading higher after Rod...
Unlock content with
Pro Subscription
5 months ago
+17.82%
FibreBiologics shares are trading higher after the company announced it issued a European patent for fibroblast delivery of tumor inhibitory agents.
